Business
American Society of Breast Surgeons (ASBrS) Resource Guide Update Recommends Cryoablation for Low-Risk Breast Cancer
IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), a developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that the American Society of Breast Surgeons' ("ASBrS") updated 2026 "Resource Guide on the Use of Transcutaneous and Percutaneous Ablation for the Treatment of Benign and Malignant Tumors of the Breast" recommends cryoablation as an option for selected patients with
About this update from Icecure Medical Ltd.
[{"type":"text","content":"IceCure's ICE3 study and the FDA Advisory Panel's favorable vote on ProSense® cryoablation's benefit-risk profile for low-risk breast cancer played a key role in the ASBrS 2026 Resource Guide update","length":210,"tagName":"p","attribs":{}},{"type":"text","content":"New medical society guidance expected to further accelerate commercial adoption of ProSense® following FDA-clearance for low-risk breast cancer in October 2025","length":159,"tagName":"p","attribs":{}},{"type":"text","content":"CAESAREA, Israel, March 9, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), a developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that the American Society of Breast Surgeons' ("ASBrS") updated 2026 "Resource Guide on the Use of Transcutaneous and Percutaneous Ablation for the Treatment of Benign and Malignant Tumors of the Breast" recommends cryoablation as an option for selected patients with biologically low-risk early-stage breast cancer. The updated guidance represents an important step toward broader clinical adoption of IceCure's ProSense® cryoablation system, which received U.S. Food and Drug Administration ("FDA") marketing clearance in October 2025 for the treatment of low-risk breast cancer in patients aged ≥70 years, with tumors measuring ≤1.5 cm, who are treated with adjuvant endocrine therapy. ProSense® is the first and only FDA cleared medical device for the treatment of breast cancer.","length":1131,"tagName":"p"},{"type":"image","alt":"IceCure Medical Logo","displaySize":"","headline":null,"caption":"IceCure Medical Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":200,"url":"https://media.zenfs.com/en/prnewswire.com/98ac7ebbcce9bffd317bd6c9e368b8ee"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TQ28_yxVQAmcG3inbpoJvw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM1MztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/98ac7ebbcce9bffd317bd6c9e368b8ee","width":400,"height":200}}},{"type":"text","content":""We believe this recognition by the ASBrS, a leading professional society, further validates cryoablation's role in modern breast cancer care and positio...